{"entity":{"id":"nct05482971","kind":"trial","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","aka":[],"tldr":"A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","summary":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET is a phase 2 interventional study registered as NCT05482971 by PharmaEssentia, with 91 participants enrolled, started 2022-09-29 and due to reach its primary completion in 2025-05-09. Interventions recorded: Ropeginterferon alfa-2b-njft (P1101).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05482971","url":"https://clinicaltrials.gov/study/NCT05482971"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05482971","phase":"2","setting":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia","sponsor":"PharmaEssentia","enrolled":91,"outcomes":[]},"route":"/trials/nct05482971/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}